The present invention provides an inhalation-type pharmaceutical composition for hypertension and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising propranolol, captopril, amlodipine besylate, losartan, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

A solid co-amorphous dispersion of valsartan according to the invention is characterized in that in the amorphous solid phase it contains valsartan, at least one non-toxic low molecular weight co-former capable of forming hydrogen bonds with valsartan molecules, an d at least one non-toxic amphiphilic solvent that solvates valsartan and co-former molecules, wherein the content of valsartan exceeds 40 mol % and 65 wt %, and the dispersion exhibits an increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan. A method for synthetizing a solid co-amorphous dispersion of valsartan by mixing valsartan with a co-former, pouring a solvent over the mixture and evaporating the solvent, wherein the physical mixture of valsartan, at least one non-toxic low molecular weight co-former capable of forming hydrogen bonds with valsartan molecules, and at least one non-toxic amphiphilic solvent is formed and subjected to mixing and homogenization in a condensed-phase, at the temperature range of 20-100° C., preferably 45-100° C., whereby excess of the solvent used is stripped off at the temperature range of 20-100° C., preferably 45-100° C., to give a final product in form of a solvated solid co-amorphous dispersion of valsartan, co-former and the solvent, which dispersion exhibits an increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan. The use of solvated solid co-amorphous dispersions of valsartan as described above, obtained as described above, in medicine and pharmacy, especially for treatment of hypertension and COVID-19 disease caused by SARS-CoV-2 virus, as a ternary formulation of valsartan, nicotinamide and a non-toxic amphiphilic solvent, preferably ethanol, n-propanol or i-propanol, characterized by increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan, and having a dual action, resulting from the synergy of ingredients supporting the therapeutic effect of valsartan. The disclosed solid dispersion according to the invention is characterized by higher solubility in comparison with that of pure valsartan, and therefore an increased bioavailability of this drug. A number of benefits results therefrom for patients (lower amount of active substance ingested), the pharmaceutical industry (lower effective dose of the active substance in preparations, resulting in reduction of production costs) and the environment (less amount of the active substance and its metabolites not absorbed by patients and released into the environment). The appropriate selection o

A solid co-amorphous dispersion of valsartan according to the invention is characterized in that in the amorphous solid phase it contains valsartan, at least one non-toxic low molecular weight co-former capable of forming hydrogen bonds with valsartan molecules, an d at least one non-toxic amphiphilic solvent that solvates valsartan and co-former molecules, wherein the content of valsartan exceeds 40 mol % and 65 wt %, and the dispersion exhibits an increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan. A method for synthetizing a solid co-amorphous dispersion of valsartan by mixing valsartan with a co-former, pouring a solvent over the mixture and evaporating the solvent, wherein the physical mixture of valsartan, at least one non-toxic low molecular weight co-former capable of forming hydrogen bonds with valsartan molecules, and at least one non-toxic amphiphilic solvent is formed and subjected to mixing and homogenization in a condensed-phase, at the temperature range of 20-100° C., preferably 45-100° C., whereby excess of the solvent used is stripped off at the temperature range of 20-100° C., preferably 45-100° C., to give a final product in form of a solvated solid co-amorphous dispersion of valsartan, co-former and the solvent, which dispersion exhibits an increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan. The use of solvated solid co-amorphous dispersions of valsartan as described above, obtained as described above, in medicine and pharmacy, especially for treatment of hypertension and COVID-19 disease caused by SARS-CoV-2 virus, as a ternary formulation of valsartan, nicotinamide and a non-toxic amphiphilic solvent, preferably ethanol, n-propanol or i-propanol, characterized by increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan, and having a dual action, resulting from the synergy of ingredients supporting the therapeutic effect of valsartan. The disclosed solid dispersion according to the invention is characterized by higher solubility in comparison with that of pure valsartan, and therefore an increased bioavailability of this drug. A number of benefits results therefrom for patients (lower amount of active substance ingested), the pharmaceutical industry (lower effective dose of the active substance in preparations, resulting in reduction of production costs) and the environment (less amount of the active substance and its metabolites not absorbed by patients and released into the environment). The appropriate selection o

A solid co-amorphous dispersion of valsartan according to the invention is characterized in that in the amorphous solid phase it contains valsartan, at least one non-toxic low molecular weight co-former capable of forming hydrogen bonds with valsartan molecules, an d at least one non-toxic amphiphilic solvent that solvates valsartan and co-former molecules, wherein the content of valsartan exceeds 40 mol % and 65 wt %, and the dispersion exhibits an increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan. A method for synthetizing a solid co-amorphous dispersion of valsartan by mixing valsartan with a co-former, pouring a solvent over the mixture and evaporating the solvent, wherein the physical mixture of valsartan, at least one non-toxic low molecular weight co-former capable of forming hydrogen bonds with valsartan molecules, and at least one non-toxic amphiphilic solvent is formed and subjected to mixing and homogenization in a condensed-phase, at the temperature range of 20-100° C., preferably 45-100° C., whereby excess of the solvent used is stripped off at the temperature range of 20-100° C., preferably 45-100° C., to give a final product in form of a solvated solid co-amorphous dispersion of valsartan, co-former and the solvent, which dispersion exhibits an increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan. The use of solvated solid co-amorphous dispersions of valsartan as described above, obtained as described above, in medicine and pharmacy, especially for treatment of hypertension and COVID-19 disease caused by SARS-CoV-2 virus, as a ternary formulation of valsartan, nicotinamide and a non-toxic amphiphilic solvent, preferably ethanol, n-propanol or i-propanol, characterized by increased water solubility—with respect to valsartan contained therein, in comparison with the solubility of pure valsartan, and having a dual action, resulting from the synergy of ingredients supporting the therapeutic effect of valsartan. The disclosed solid dispersion according to the invention is characterized by higher solubility in comparison with that of pure valsartan, and therefore an increased bioavailability of this drug. A number of benefits results therefrom for patients (lower amount of active substance ingested), the pharmaceutical industry (lower effective dose of the active substance in preparations, resulting in reduction of production costs) and the environment (less amount of the active substance and its metabolites not absorbed by patients and released into the environment). The appropriate selection o

This invention relates to the use of nucleoside, nucleotide and other compounds which are inhibitors or terminators of viral RNA dependent RNA polymerases or inhibitors of exonucleases as antiviral agents. These antiviral agents can be used alone or in combination with other polymerase or exonuclease inhibitors, helicase inhibitors, HCV NS5A inhibitors, HIV integrase inhibitors and HCV NS3-4A and other protease inhibitors to treat viral infections such as SARS-CoV-2, the causative agent of the COVID-19 infection.

The present invention recognizes that there is a need for the prophylaxis or treatment of COVID and COVID-19. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using various pharmaceutical compositions. A second aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of antimalarial drugs and antiviral drugs. A third aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using nanoparticle formulations that include pharmaceutical compositions. A fourth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of various pharmaceutical compositions. A fifth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using a polio vaccine and pharmaceutical compositions.

The present invention recognizes that there is a need for the prophylaxis or treatment of COVID and COVID-19. A first aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using various pharmaceutical compositions. A second aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of antimalarial drugs and antiviral drugs. A third aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using nanoparticle formulations that include pharmaceutical compositions. A fourth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using combinations of various pharmaceutical compositions. A fifth aspect of the present invention generally relates to methods of prophylaxis or treatment of COVID or COVID-19 using a polio vaccine and pharmaceutical compositions.

Provided herein are methods and compositions related to using ebselen for treating acute lung infections and related conditions or diseases. In certain embodiments the methods relate to treating coronavirus-mediated lung injuries. Also provided are methods of treating a patient who has a confirmed or suspected viral lung infection, comprising administering a therapeutically effective amount of ebselen to a patient suffering from a viral lung infection. Also provided are methods of treating a patient who has or is at risk for cytokine release syndrome (CRS), comprising administering an effective amount of ebselen to a patient who has, or is at risk for, CRS. In another aspect, provided herein is a pharmaceutical comprising ebselen, and an antiviral agent that is useful in the methods of this disclosure.

Provided herein are methods and compositions related to using ebselen for treating acute lung infections and related conditions or diseases. In certain embodiments the methods relate to treating coronavirus-mediated lung injuries. Also provided are methods of treating a patient who has a confirmed or suspected viral lung infection, comprising administering a therapeutically effective amount of ebselen to a patient suffering from a viral lung infection. Also provided are methods of treating a patient who has or is at risk for cytokine release syndrome (CRS), comprising administering an effective amount of ebselen to a patient who has, or is at risk for, CRS. In another aspect, provided herein is a pharmaceutical comprising ebselen, and an antiviral agent that is useful in the methods of this disclosure.

Provided herein are methods and compositions related to using ebselen for treating acute lung infections and related conditions or diseases. In certain embodiments the methods relate to treating coronavirus-mediated lung injuries. Also provided are methods of treating a patient who has a confirmed or suspected viral lung infection, comprising administering a therapeutically effective amount of ebselen to a patient suffering from a viral lung infection. Also provided are methods of treating a patient who has or is at risk for cytokine release syndrome (CRS), comprising administering an effective amount of ebselen to a patient who has, or is at risk for, CRS. In another aspect, provided herein is a pharmaceutical comprising ebselen, and an antiviral agent that is useful in the methods of this disclosure.